Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The preclinical start-up is working towards the development of first-in-class small molecule (IST-01) inhibitors of transglutaminase 2 (TG2), one of the major crosslinking enzymes in the human body, which becomes more active during aging resulting in fibrotic diseases.
Lead Product(s): IST-01
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: IST-01
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2023